← Back to Screener
Acumen Pharmaceuticals, Inc. Common Stock (ABOS)
Price$2.69
Favorite Metrics
Price vs S&P 500 (26W)40.69%
Price vs S&P 500 (4W)-12.67%
Market Capitalization$196.42M
All Metrics
Book Value / Share (Quarterly)$1.16
P/TBV (Annual)0.73x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.91
Price vs S&P 500 (YTD)26.27%
Net Profit Margin (TTM)-509.72%
EPS (TTM)$-2.00
10-Day Avg Trading Volume0.51M
EPS Excl Extra (TTM)$-2.00
EPS (Annual)$-1.70
ROI (Annual)-48.29%
Cash / Share (Quarterly)$1.93
ROA (Last FY)-42.68%
EBITD / Share (TTM)$-2.05
ROE (5Y Avg)-32.47%
Operating Margin (TTM)-550.00%
Cash Flow / Share (Annual)$-1.91
P/B Ratio2.79x
P/B Ratio (Quarterly)1.81x
Net Income / Employee (Annual)$-2
ROA (TTM)-75.67%
EPS Incl Extra (Annual)$-1.70
Current Ratio (Annual)4.07x
Quick Ratio (Quarterly)3.92x
3-Month Avg Trading Volume0.67M
52-Week Price Return147.27%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.84
P/S Ratio (Annual)136.40x
Asset Turnover (Annual)0.03x
52-Week High$3.60
EPS Excl Extra (Annual)$-1.70
26-Week Price Return44.68%
Quick Ratio (Annual)3.92x
13-Week Price Return58.14%
Total Debt / Equity (Annual)0.44x
Current Ratio (Quarterly)4.07x
Enterprise Value$173.591
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-509.03%
Cash / Share (Annual)$1.93
3-Month Return Std Dev96.10%
Net Income / Employee (TTM)$-2
ROE (Last FY)-56.10%
EPS Basic Excl Extra (Annual)$-1.70
Total Debt / Equity (Quarterly)0.44x
EPS Incl Extra (TTM)$-2.00
ROI (TTM)-87.07%
P/S Ratio (TTM)136.40x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.60
Price vs S&P 500 (52W)117.44%
Year-to-Date Return28.91%
5-Day Price Return8.37%
EPS Normalized (Annual)$-1.70
ROA (5Y Avg)-28.31%
Net Profit Margin (Annual)-509.03%
Month-to-Date Return15.25%
Cash Flow / Share (TTM)$-1.10
EBITD / Share (Annual)$-1.70
Operating Margin (Annual)-549.31%
LT Debt / Equity (Annual)0.32x
ROI (5Y Avg)-30.50%
LT Debt / Equity (Quarterly)0.32x
EPS Basic Excl Extra (TTM)$-2.00
P/TBV (Quarterly)0.49x
P/B Ratio (Annual)1.81x
Pretax Margin (TTM)-509.72%
Book Value / Share (Annual)$1.16
Price vs S&P 500 (13W)57.45%
Beta0.41x
Revenue / Share (TTM)$0.00
ROE (TTM)-111.27%
52-Week Low$0.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.42
4.42
4.42
4.42
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ABOSAcumen Pharmaceuticals, Inc. Common Stock | 136.40x | — | — | — | $2.69 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing ACU193, a monoclonal antibody designed to treat Alzheimer's disease by targeting amyloid-beta oligomers. The company's therapeutic approach seeks to address what management identifies as a key underlying cause of neurodegeneration.